COO NYSE
The Cooper Companies, Inc.

What happened
-2.35% 2026-03-04

From 2026-03-04 session.

Rothschild downgrade to Neutral pressures shares as two-day slide deepens

Cooper Companies stock declined 2.4% following the company's fourth quarter and full year 2025 earnings announcement on December 4, 2025. The company reported fourth quarter GAAP diluted earnings per share of $0.43, down 27% from the prior year, though non-GAAP diluted EPS of $1.15 was up 11%. Fourth quarter revenue reached $1,065.2 million, up 5% or 3% organically.

Full analysis covers our editorial take, sources, and more.

Track COO — big moves explained

What happened. Why it matters. 30 seconds.

COO explained

What does The Cooper Companies, Inc. do?

Cooper Companies is a San Ramon, California-based medical device firm operating through two divisions: CooperVision, one of the world's largest contact lens manufacturers, and CooperSurgical, a fertility and women's healthcare business. The company generates roughly $4.1 billion in annual revenue and has been expanding its myopia control lens portfolio globally. Today's decline followed an analyst downgrade that questioned near-term upside after the stock's recovery from its 12-month low.

How does WTF Just Happened track The Cooper Companies, Inc.?

We watch COO for moves that stand out from normal trading -- the kind of day that makes you ask "WTF just happened?" When The Cooper Companies, Inc. moves beyond its usual range, our AI digs through 15-20 news sources to piece together what drove it. No predictions, no trading advice -- just a clear explanation in about 30 seconds.

See what else moved today →

What a WTF analysis looks like

From a recent analysis

The decline is unremarkable at 0.3 sigma — well within the stock's normal daily range, which has included swings of 5-10% routinely this month. The Technology sector's 2.28% drop and semiconductors' 4.17% plunge provide the most relevant context, though the stock's 1.91% decline actually outperformed both benchmarks. The stock underperformed its specific peer group average (+1.5%) by 3.4 percentage points, but peer composition matters: ZS and FTNT are cybersecurity names that rallied on sector-specific news, making the comparison less informative than the broader tech selloff. With Q4 earnings due after the close today, pre-report positioning likely suppressed buying interest — the stock has recovered roughly 14% from its February 20 low following the Blue Owl financing failure, and some profit-taking ahead of a high-stakes print is consistent with the 1.4x volume reading.
Get analysis like this for COO

More Healthcare stocks we track

UNHJNJLLYPFEABTMRKTMOABBV